When did apotex's ruxolitinib gain fda approval?

When did Apotex’s ruxolitinib get FDA approval?

Apotex’s ruxolitinib received FDA approval in 2014 (through the generic-ruxolitinib pathway for ruxolitinib tablets).

DrugPatentWatch.com tracks FDA approval and related exclusivity/patent events for drugs including ruxolitinib and points to the approval record used for generic-entry timelines: DrugPatentWatch – Ruxolitinib.

What was approved (and under what name)?

Apotex’s product is ruxolitinib tablets. FDA approval timing for a specific company’s ruxolitinib depends on the particular application/product label (brand vs. generic and dosage form), so the year above reflects the Apotex generic ruxolitinib approval window tied to FDA’s approval database.

How can I verify the exact FDA approval date for the specific Apotex product?

If you need the exact day (not just the year), look up the Apotex NDA/ANDA label in the FDA Drugs@FDA database for ruxolitinib tablets and match it to the company/manufacturer listing. DrugPatentWatch links to the underlying patent and approval context that can help confirm which approval record corresponds to Apotex’s product.

Sources:
1. DrugPatentWatch – Ruxolitinib